• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    The invention concerns pharmaceutical compositions having analgesic, and in some cases, in addition anti-inflammatory properties, for use in the treatment of painful inflammatory joint disease, which compositions contain as active ingredient a new or old 1-alkyl (or cycloalkyl)-4-(N-alkanoyl)substituted-amino-tetrahydro-1,3,5-triazine- 2,6-dione of the formula: <IMAGE> I or a base-addition salt thereof.
    公开号:SU890976A3
    申请号:SU782587045
    申请日:1978-02-20
    公开日:1981-12-15
    发明作者:Тревор Кэй Ян；Хепворт Уолтер；Дуглас Браун Эдвард
    申请人:Империал Кемикал Индастриз Лимитед (Фирма)；
    IPC主号:
    专利说明:

    3 The process is preferably carried out in the presence of a hydrocarbon diluent or solvent, for example, luol or xylene. Depending on the nature of R and R, some of the compounds described by formula D may have one or more asymmetric carbon atoms and may therefore be in the racemic and optically active form. The invention relates to those racemic or optically active forms of such compounds that possess the indicated properties, and the optically active forms can be obtained by known methods by cleavage of the corresponding racemate or by synthesis from optically active starting materials. Base salts of a compound of formula I are, for example, an alkali metal or alkaline earth metal salt, for example, sodium, potassium, calcium, or a magnesium salt, an aluminum salt, for example, a double aluminum hydroxide salt, a copper salt or an organic base salt pharmaceutically acceptable cation, for example, triethanolamine or benzylamine. Particular preferred compounds of formula D are 1-isopropyl-4- (N-acetyl) cyclopropylamino-tetrahydro-1, 3,5-triazine-2,6-dione, 1-isopropyl-4- (H-acetyl) -penta -3-ylam but -tetrahydro-1,3,5-triazin-2,6-dio and l-M3onpom n-4- (N-acetyl) -cyclohexyl-amino-tetrahydro-1, 3,5-triazin-2 , 6-dione. When carrying out the process it is better to use an excess amount of acetylating reagent, which can itself serve as a diluent or solvent. By using acetic anhydride as the acylating agent, acetic acid can also be obtained, which can be removed by standard procedures using distillation. The starting materials of the formula TG can be obtained, as indicated in the examples, by reacting the amine described by the formula R NH ii with 4-alkylthio-1,3,5-triazine, described by the formula III .. QV-H: kX in which R corresponds to C-alkyl, for example, methyl. The amine described by the formula R NH | j is used in the form of its salt with C alkanoic acid, and the reaction is preferably carried out at temperatures which are in the range of 100-250 ° C. In this case, a suitable mercury solvent or solvent is used, for example dimethylformamide. 4-Alkyl-thio compounds of the formula 1IT can be obtained by known methods developed for the synthesis of analogous 1,3,5-triazine-2,6-diones 1. The compounds of formula I are moderately acidic and react with weak bases, for example alkali metal carbonates, to form the corresponding alkali metal salts. If it is necessary to obtain a pharmaceutically acceptable salt obtained by attaching a base, the compound of the formula D is reacted with a base suitable for this purpose. The analgesic properties of the compounds of Formula D can be demonstrated during the standard test by measuring the stopping period of a writhing mouse that had intraperitoneal injection of bristlecholine using Method 2. In general, the compounds of Formula I show significant activity during this test when administered to an experimental animal. through a mouth dose of 50 mg / kg or less, in the complete absence of any toxic effects when using an active dose, and Extensive compounds of the formula T, for example, l-isopropyl-4 - {(N-acetyl) -pent-3-ylamino-J-tetrahydro-1, 3,5-triazine-2,6-dione, show significantly less activity when administered through A mouth dose of 5 mg / kg body weight or much less. In addition to the analgesic properties, compounds of the formula T have an anti-inflammatory effect, which can be demonstrated using either of the two or two standardized tests: when creating arthritis in rats using stimulant, a ditch based on the 3J method; edema in rats5 caused by the introduction of Icelandic moss using Method 4 Compounds of formula 1, which have good anti-inflammatory properties, show activity in either of two or both of these tests with a dose of substance administered through the mouth equal to or less 50 mg / kg of weight5, which is administered as a daily dose for i4 dkey during the test (a) or as a razonon dose for the test (c), without any toxic side effects when using this dose. Novyget compounds of formula 1. Having good anti-inflammatory properties are, for example, 1-ETSH1-4- {N-acetyl) p-propyl-mino,. 1-p-propyl-4 (M-acetyl) -p-propylamis and 1-isopropyl-4- (L-apethyl) benzyl-1-tetrahydro-1,3,5-triazin-2.6-dcon, Some of the compounds of the formula G are also have the property of stopping prostaglandin enzyme synthesis. This property can be demonstrated. But in a standard exponent. carried out in Vi tgo5, which includes the use of prostaglandin synthetase isolated from the sheep germ cell. Those compounds of formula T, which stop prostagland synthetase, provide this process at an in vitro concentration of x within 10 M or less. Examples of compounds of the formula T which iip Kpa: L;, a;: T;:.: L of the prostaglandin thetase are, for example, the compound 1-isoprosh; l-4- (M-acetyl) -benzylamino-tetrahydro-1 , 3,5-triazine-2,6-dione. Synthetase-inhibiting prostaglandin compounds are known to, for example, indomethine or flufenamic acid, are effective in clinical use in the case of treatment; and in the treatment of accompanying 66ne3HeHHjit: iH sensations of inflammatory joint diseases, for example, HJTH arthritis. ostaarthritis. When used to create the aforementioned pharmacological effects in warm-blooded animals, the compounds of the formula T can be administered as follows: a) for the analgesic effect at a daily dose, for example, 0.1-25 mg / kg (for a human being this is equivalent to a daily dose administration of, for example, 2.5-626 Mrj; c) to provide an anti-inflammatory effect with a daily oral dose, for example, 1-550 mg / kg of a compound of Formula 5 having anti-inflammation; m effect (for a person, this corresponds to a full daily dose of 25, 2-1250 mg, for example); c) dp suppressing prostagmental synthetase {. aik in vivo at a daily dose, eg 15 ger, 1–50 mg / kg of active iagradiant formula I, which has the property of suppressing prostaglgide synthetase on (, Especially in humans, this is equivalent to the full dose of daily intake equal to, for example, 25-1250 mg of the active and gradient of the formula I or its salt, obtained by addition of the base, as already indicated. Compounds of the formula G used in the form of the usual pharmaceutical compounds Gg can be used, eg ger; accompanied by pain and K11 inflammations of joints, such as arthritis and osteoarthritis. Example 1. 4.0 g of 1-isopropyl-4-CЕ-1-hlopropylamine tetrahydro-1,3 5-trzazin-2, 6-dione is heated with reverse Kbs: -i with a holochglnik at 50 ml of acetic acid hydride for 3 h. Beat; tx aq of acetic acid is then distilled off in vacuo, and the resulting residue is high: "n-hexane containing a small amount of ester. The brown solid is separated and recrystallized from a mixture of carbon tetrachloride and petroleum ether (so kip. BW-cc) to obtain 55% of 1-i-3ponHn-A- (N-acetyl, cycloproxamine-tetrahydro-1, 3,5-triazin-2, 6-dione, mp. 118-119 C. Initial the compounds are obtained in the following manner: 6.0 g of 1-isopropyl-4-methylthiotetrahydro-1, 3,5-triazine-2,6-dione and 17.85 g of cyclopropylamine acetate are heated together and stirred at .150 ° C for 3 hours. The mixture is then cooled and 150 ml of water is added to it. The resulting solid material is collected, washed with water and dried 78909768
    sewed in order to obtain 1-isopropane. Example 2. For the same method-4-cyclopropylaminotetra-hydroke as in example 1, the following 3.5, tri-triazine-2,6-dione, t. square 237 is the blow of a compound of formula 1 with an output of 239 C. a house of 60-90%. f m 1
    9 cyclohexyl 253-258
    101- (phenyl) ethyl 1697171
    11pent-3-yl 233-256
    12hex-3-yl syrup (at 13 hept-4-yl syrup (at 144-chlorophenyl 248-250
    154-methylphenyl 286-288
    Notes: syrups are homogeneous, which is confirmed by thin layer chromatography (SiO (: ethyl acetate / toluene acetic acid; 2:35:63 v / v) and have the following characteristics NMR spectroscopy (and
    tagging (c)) 989097610 14 4-chlorophenyl 248-250 15. 4-methylfensh1 214-216 Note: syrups are homogeneous according to thin layer chromatography (SiOj: acetic acid (ethyl acetate): toluene 2:80:18 volumes per volume) and have the following characteristics of the NMR spectrum, determined at 60 MHz in a solution of CaCj when tetrametypsilane (TMS) is used as an internal standard. a) (L (ppm): 1, doublet (d) 6 protons, (SNE) 2.CH1; 1.77-1.9 doublet (d), 3 protons,) 2.0 singlet (s ), 3 protons, 4.7-5.3 multiplet (t), 1 proton, (CH3) 6.5-6.9 quartet (q), 1 proton, CH HPVif, 7.26 singlet (S), 5 aromatic protons; c) L (ppm) (100 MHz): 0.86-1.0 t, 6. protons, СН з (СН / г), 1 СННН СНз; 1.15-1.35 (t, 3 protons, CH CH / jCH / L CHCHD, CH 3); 1.42-1.50 d, 6 protons, (CHjJoCHJ; 1.65-2.35 (m, 4 protons, CHjCHiCHiCHCH CHj); 2.43 (s, 3 protons, NCOCH,), 4.05- 4.40 t, I proton, СНз (СНо,) г1 СНСНпСНаЗ; 4, 85-5,2 m, 1 proton, (СНз) с) оЛ- (ppm): 0.7-1.1 (t, 6 protons, CH CHijCHQiCH-); 1.1-1.7 (m, 4 protons, CH HijCHQ CH) -; 1.42-1.53 td, 6 protons, (1.77-2.35 (ffl, 4 protons, CHjCHfjCHjj CH); 2.47 (s, 3 protons, NCOCH,); 4.05-4.60 (m, 1 proton, CHzSN CHd, CH); 4.73-5.40 Cm, 1 proton, (CHj). The starting materials are -1,3,5-triazin-2,6-dione with 1.5 get similarly, with a 2.0 molar excess, the corresponding reaction of vinic amine as its -4-methylthio-tetrahydroacetate accordingly. Intermediate compounds and mp., ° C
     1890976
    pa (determined at 60 MHz in a CdCij solution using TMS as an internal standard):
    a) ((ppm): 0.77-1.71 (t, 6 protons, CHjCH CHopHCHrjCH); 1.42 and, 52 (, 6 protons, - (CHni) 1.17-2.07 (t, 6 protons,); 3,62-4,32 fm (wide) proton, СНзСН, (СНСНпСНд; 4,72-5,37 (t, 1 proton, (СЕ) СН), 8.17 Id ( wide), 1 proton,
    c) o (ppm): 0.7–9.1 (t, 6 protons, CHijCH CH CH); 1.1-1.19 (p, 8 protons,); 1.4-1.53 d, 6 protons, (CH) 3.6-4.3 m (broad), 1 proton, CHo, CHQ.CH, CH} I 4.7-5.3 Gt, 1 drton , (CH2)) j, CH.
    Example 4. A suspension of 1-isopropyl-4- (M-acetyl) cyclohexyl-aminotetrahydro-1, 3,5-triazin-2, 6-dione (10 mM) in a mixture of water (50 ml) and 1 is prepared, 2-dimethoxyethane (10 ml). Sodium bicarbonate (10 ml) in water (50 ml) is then added to the stirred suspension. After the mixture has been quenched for 1 hour at room temperature, the solution is filtered and the filtrate is evaporated in vacuo. The solid residue is triturated with a small amount of 1,2-dimethoxyethane so that the semi-R
    connection 1 2
    N-propyl
    cyclohexyl i-propyl
    2,4-dimethyl-pent-3-yl
    exo-norbori-2-yl
    3 4 5
    i-propyl
    i-propyl
    Pent-3-yl H-Propyl
    NON-5-IL
    i-propyl
    Notes; Non-crystalline compounds: homogeneous, judged by TLC analysis (system as in the first part of Example 3) and have the following characteristics of the NMR spectrum (determined at 100 MHz in solution using TMS as an internal standard):
    a) tf-0,8-l, 15 (t, 3 protons, CHjCHa); 1.8-2.15 (m, 12 protons, CHj-CH + - (CH,); 2.43 (m, 3 protons, COCHg);
    3.78-4.32 (m, 3protons,) V
    c), 50 (d, 6 protons, (CHi,) 2.CH ;; 2.22 (e, 3 protons, COCHj); 2.30-2.42 (2s, 2 protons, norbornyl and Cd-H) ; 4.0 (t, 1 proton, norbornyl C / -enzo-E}, sep12
    Sodium 1-isopropyl-4- (N-acetyl) cyclohexylamino-tetrahydro-1,3,5-triazine-2,2-dione sodium salt with a significant quantitative yield in the form of a white solid, the microanalysis of which gives satisfactory results.
    Example 5. Using the procedure described in example 1, the following compounds of formula I are obtained in 30% to 75% yield by reacting the corresponding compound of formula 11 with an excess of acetic anhydride.
    i
    M.p., with foam (aj
    124-126
    (from the air)
    foam (in) resin (s)
    95-98
    (from the air)
    69-70 According to the formula of the method, according to reagents, 1 proton, (CH; 11.1 (ps, s, 1 proton, -NH-); с) rf-0.83-1.07 rt, 3 protons, SI ( CHO) 2-1.12-1.68 (d, 6 protons, (CH3) 2CH; + t, 3 protons, CHj-CH- (CHti), 2 protons, CHjCH-CHnCHi CHo); 1.72-2.3 (m, 2 protons, CH CH-CH / j CHQCHj); 2.45 (s, 3 protons, COCHj); 4.28-4.67 sextuplet, 1 proton, CHj-CH () (- СНз1; 4.78-5.27 septilet, 1 proton, (CHa) tCH. These starting materials 11 were obtained using the procedure described in example 1, and 1-isopropyl- (or n-propyl) -4-methylthiotetrahydro-1,3,5-triazin-2, 6-dione with an excess of the corresponding alkylamine in the form of its acetate.
    Intermediate compound
    one
    T. Kip., C 277-278
    cyclohexyl
    1-propyl
    1-propyl
    4 5
    i-propyl C-propyl t f
    where r means
    C is an alkyl radical, R is a C dialkyl radical, carrying a C alkoxy radical, a Cj.g cycloalkyl or C 2 alkenyl radicals, a Cy alkyl radical where the connecting (i is a carbon atom is secondary, benzyl, or 1- (phenyl) ethyl
    2,4-dimethyl-pent-3-yl
    254-256
    exonorborn-2-yl
    pent-2-yl pent-3-yl
    .N
     sr
    WITH
    权利要求:
    Claims (4)
    [1]
    subjected to interaction with acetic inhydride at 80-150 ° C, followed by 6 p-propyl HON-5-Ilmsol (c) Note: According to TLC analysis (the system is the same as in the second part of example 3, the resins are homogeneous and have the following characteristics of the NMR spectrum : a) dt (90 MHz); Oj7-i, 05 ft, 3 protons, SPa, CH (CH,) ,,; 1.1-1.72 d, 6 protons, (CH,) + t, 4 proton, CHj-CH (CHi) (iCH j; + d, 3 protons, CHjCH- (CHd) 3.78-4j2 m (broad), 1 proton, CHjCH "(CHii) (j.dHo,; 4.73 -5.28 Seplitt, 1 proton, (c) s (60 MHz): 0.8-l, lCt (broad), 6 protons, CHij | (CHii) u, CH; 1.2-1.7 m, 12 protons, CHj (CHfj) + d, 6 protons, CCHo,) (3.76, 4.27 tons (broad), 1 proton,; 4.87–5.32 Septiple , 1 proton, (CH) (3iCHjl. Claims of the invention. Method of obtaining hydro-1,3,5-triazine-2,6-dione derivatives G 1 cioeK3. 0 radical, or phenyl, or phenyl radical, bearing the substituent chosen from halogen atoms or) strong radicals; or where (means n-stitched or ethyl radic aJi and R means n-propyl radical or R means an isopropyl radical and R is a 3,3-dimethylbutyl radical. OR their salts, characterized in that the compound of the formula // 15 8909 isolates the desired product as a base or salt. 2. Method pop.1, which is distinguished by the fact that the process is carried out in the presence of a hydrocarbon solvent or solvent, the priority is recognized by itself. 02.21.77 R is a C-alkyl radical, C is an alkyl radical bearing the C alkoxy-S radical, (1.-cycle is an alkyl or C. alkenyl radical, benzyl or phenyl, or a phenyl radical bearing a substituent selected from halogen atoms or C-alkyl radicals and clause 2 of the formula, For the rest of the signs, priority: dated 02/20/78.616 Sources of information taken into account during the examination 1. England patent No. J464248, class C 2 C, published on 09.02.77 .
    [2]
    2. Hackett D., BackettW. Drug effeptd In and novel btphaslc writhing syndrome Induced by acetylcholine | n mice, Europ. J. Pharmacol. 1975, v. 30, p. 280.
    [3]
    3. Newbould V.V. ;; Chemotherapy of artrltis induced in rats by Mycobacterial Adjuvant, British J. Pharmacology, 1963, .- v. 21, p. 127.
    [4]
    4. Winter, S.A., Proceedings of the Society of Experimental Biology, N.-J., 1962, V. Ill, p. 544..
    类似技术:
    公开号 | 公开日 | 专利标题
    EP0591528B1|1998-12-23|PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVE AND ANTI-INFLAMMATORY CONTAINING THE SAME
    WO1992007830A2|1992-05-14|Oxindole peptide antagonists
    SU890976A3|1981-12-15|Method of preparing derivatives of tetrahydro-1,3,5-triazin-2,6-diones or thzeir salts
    CA1108138A|1981-09-01|Triazine derivatives
    HU190541B|1986-09-29|Process for preparing disubstituted proline derivatives
    EP0272478B1|1993-01-20|Glycyrrhetic acid derivatives and use thereof
    IE55872B1|1991-02-14|Derivatives of omega-amino acids,the preparation and utilisation thereof,and the compositions containing these derivatives
    SK147897A3|1998-05-06|Azacycloalcane derivatives, preparation thereof and their applications in therapy
    EP0771790B1|2003-10-01|Process for preparing 1-substituted pyrrole-3-carboxylic acid derivatives
    Tschudy et al.1959|Malonic Ester Synthesis of δ-Aminolevulinic Acid. The Reaction of N-3-Bromoacetonylphthalimide with Malonic Ester
    EP0285270B1|1992-06-03|A method for producing 1-propargyl-2,4-dioxoimidazolidine
    EP0220653A2|1987-05-06|3-Aminocarbonyl-1,4-dihydropyridine-5-carboxylic acid compounds, process for preparation and use thereof, and pharmaceutical composition containing the same
    HU176231B|1981-01-28|Process for producing 4a-aryl-octahydro-1h-2-pyridine derivatives
    IE902242A1|1991-01-16|Novel Spirofurane Derivatives
    JPH0710863B2|1995-02-08|Novel derivative of 4-OH quinolinecarboxylic acid substituted at position 2 with an etherifiable or esterifiable dihydroxy group, a process for its preparation and its use as a medicament
    JP3999861B2|2007-10-31|Novel pyridazine derivatives and pharmaceuticals containing the same as active ingredients
    US4496577A|1985-01-29|Imidazolidinone prostaglandins, compositions and use
    Finkelstein et al.1966|Synthesis of trans-2-Cyclohexyloxycyclopropylamine and Derivatives
    WO1991011444A1|1991-08-08|Piperazine compound, production thereof, and medicinal use thereof
    IL37431A|1974-10-22|Pharmaceutical compositions containing derivatives of thiazolino|pyrimidin-5-one,certain such novel derivatives and their preparation
    CA1131635A|1982-09-14|Pharmaceutical compositions
    SU679143A3|1979-08-05|Method of producing arylaminopyrimidine derivatives
    KR100460414B1|2005-01-26|Process for preparing 1-substituted pyrrole-3-carbozylic acie deriavatives
    KR810001819B1|1981-11-16|Process for the preparation of tetrahydro 1,3,5-triyzine-2,6-diones
    FI88039C|1993-03-25|PROCEDURE FOR THE FRAMSTATION OF 2,3-DIHYDRO-1- | -4 | -PYRIDINONE
    同族专利:
    公开号 | 公开日
    DD134091A5|1979-02-07|
    FI64152B|1983-06-30|
    SE7801930L|1978-08-22|
    CH637646A5|1983-08-15|
    DK67978A|1978-08-22|
    AU3311278A|1979-08-16|
    ES467170A1|1979-08-16|
    DE2807381A1|1978-08-24|
    JPS53105487A|1978-09-13|
    ATA127178A|1980-02-15|
    NZ186406A|1984-08-24|
    AR220120A1|1980-10-15|
    ZA78671B|1978-12-27|
    LU79092A1|1979-05-25|
    NL7801921A|1978-08-23|
    PL204641A1|1978-12-04|
    IL54026A|1983-06-15|
    GR62157B|1979-03-01|
    GB1599518A|1981-10-07|
    BE864124A|1978-08-21|
    AU519803B2|1981-12-24|
    PT67668B|1979-09-20|
    IT1158652B|1987-02-25|
    ES476428A1|1979-05-01|
    CS208464B2|1981-09-15|
    SE440775B|1985-08-19|
    ZM1878A1|1981-06-22|
    NO780576L|1978-08-22|
    PL107871B1|1980-03-31|
    AT358592B|1980-09-25|
    HU182653B|1984-02-28|
    HU176980B|1981-06-28|
    US4156002A|1979-05-22|
    FR2381034B1|1980-09-19|
    IE46650B1|1983-08-10|
    PT67668A|1978-03-01|
    IT7820500D0|1978-02-21|
    CA1117867A|1982-02-09|
    SU867303A3|1981-09-23|
    PL109995B1|1980-06-30|
    FI780529A|1978-08-22|
    CS208463B2|1981-09-15|
    ES476427A1|1979-04-16|
    FI64152C|1983-10-10|
    FR2381034A1|1978-09-15|
    MW478A1|1980-02-13|
    IE780217L|1978-08-21|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    SE347973B|1965-07-21|1972-08-21|Takeda Chemical Industries Ltd|
    US4035365A|1973-11-01|1977-07-12|Imperial Chemical Industries Limited|Triazinediones|
    JPS5623425B2|1973-11-09|1981-05-30|
    GB1543037A|1975-02-05|1979-03-28|Ici Ltd|Selective herbicidal triazine-diones|DE2962124D1|1978-05-26|1982-03-25|Ici Plc|Analgesic 6-acylaminotetrahydro-1,3,5-triazine-2,4-dione derivatives, pharmaceutical compositions thereof, and process for their manufacture|
    GB8629567D0|1986-12-10|1987-01-21|Boots Co Plc|Therapeutic agents|
    US6348216B1|1996-06-10|2002-02-19|Knoll Pharmaceutical Company|Ibuprofen and narcotic analgesic compositions|
    US6361794B1|1996-06-12|2002-03-26|Basf Corporation|Method of making ibuprofen and narcotic analgesic composition|
    JP5692747B2|2009-02-13|2015-04-01|塩野義製薬株式会社|Novel triazine derivative and pharmaceutical composition containing the same|
    EP2604260B1|2010-08-10|2017-05-10|Shionogi&Co., Ltd.|Novel heterocyclic derivatives and pharmaceutical composition containing same|
    CN103153968B|2010-08-10|2016-02-03|盐野义制药株式会社|Triazole derivative and containing its pharmaceutical composition with analgesic activity|
    US9550763B2|2012-02-09|2017-01-24|Shionogi & Co., Ltd.|Heterocyclic ring and carbocyclic derivative|
    TWI637949B|2013-06-14|2018-10-11|塩野義製藥股份有限公司|Aminotriazine derivative and pharmaceutical composition comprising the same|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    GB7183/77A|GB1599518A|1977-02-21|1977-02-21|1,3,5-triazine-2,6-diones and pharmaceutical compositions thereof|
    [返回顶部]